|Bid||18.00 x 1000|
|Ask||18.75 x 2900|
|Day's Range||17.70 - 18.65|
|52 Week Range||15.02 - 25.31|
|Beta (5Y Monthly)||1.61|
|PE Ratio (TTM)||18.23|
|Earnings Date||Apr 28, 2020 - May 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.42|
There's been a notable change in appetite for Exelixis, Inc. (NASDAQ:EXEL) shares in the week since its annual report...
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis’ management team will provide a corporate overview at the following investor conferences in March:
Exelixis (EXEL) delivered earnings and revenue surprises of 46.67% and -0.15%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Exelixis, Inc. (NASDAQ: EXEL) today announced enrollment of the first 100 patients in COSMIC-311, a phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) versus placebo in patients with radioactive iodine-refractory differentiated thyroid cancer who have progressed after up to two vascular endothelial growth factor (VEGF) receptor-targeted therapies.
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and full year 2019 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.
Buying shares in the best businesses can build meaningful wealth for you and your family. While not every stock...
Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2019 financial results will be released on Tuesday, February 25, 2020 after the markets close. At 5:00 p.m. EST / 2:00 p.m. PST, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company’s website.
In a market flexing trillion-plus market caps and where 'FOMO' is the questionable ticker of choice, mid-cap growth stocks can be an attractive alternative for many investors' portfolios. Let's take a look at three of these companies which are also in position on their price charts for risk-adjusted purchases.From Apple (NASDAQ:AAPL) to Microsoft (NASDAQ:MSFT) and most recently Amazon (NASDAQ:AMZN) and Alphabet (NASDAQ:GOOGL), the once-elusive, then exclusive $1 trillion market cap club has become a bit more inclusive these days. Moreover, the inclusion into this large-cap club has been driven by a common and unsustainable thread called FOMO.This "fear of missing out" behavior on the part of investors has also put most of these companies' price charts in a much riskier position. Because of their obvious influence, warnings the market has gone too far, too fast are spreading faster than the coronavirus. Yet there's more to the market.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 U.S. Stocks to Buy on Coronavirus Weakness In a market made up of stocks, today's price action and valuations aren't universally problematic. Mid-caps with valuations of $2 to $10 billion and more specifically, mid-cap growth stocks which sport solid business trends to support larger price gains, are available if you know where to look. Right now three companies of this caliber have caught our attention in a very big way. Alteryx (AYX) Source: Charts by TradingViewData science and analytics outfit Alteryx (NYSE:AYX) is the first of our mid-cap growth stocks to buy. The company is scheduled to report earnings this Thursday evening. Guidance from Alteryx's management calls for the company to grow sales by roughly 45% year-over-year.Expectations in front of the release are high, but rightfully so according to a recent analyst note from Wedbush. This mid-cap growth stock also has the benefit of a price chart built for success. Shares of AYX are currently forming a small handle consolidation within a monthly chart cup base. Further, as a first-stage corrective base and fairly recent IPO, there are plenty of reasons to see Alteryx stock as an even more attractive buy.Alteryx Strategy: I see AYX stock as a purchase in front of earnings. However, as a former options market-maker, I'd also suggest using a limited and reduced risk, slightly out-of-the-money bull call spread to improve investor's risk profile. Exelixis (EXEL) Source: Charts by TradingViewExelixis (NASDAQ:EXEL) is the next of our mid-cap growth stocks to buy. This cancer-fighting biotech is profitable and sports double-digit revenue growth which offers an almost numbingly price multiple of just 19x earnings. Need I say more? That's not a problem.Technically, shares of Exelixis have confirmed a bullish higher-low pattern above former key resistance dating back to 2002. The price action follows a successful test of this threshold in late 2018 during the broader market's correction. And with Exelixis' stock's stochastics confirming this pattern strength, the time to buy shares is now. * 7 Strong Value Stocks to Buy for 2020 Exelixis Strategy: With earnings slated for later this month, I like approaching this mid-cap growth stock with a married put strategy. This long stock and long put combination contains risk while allowing for open-ended upside in front of what's sure to be a volatile report. Simply Good Foods (SMPL) Source: Charts by TradingViewWhen it comes to the trend of healthier eating, Simply Good Foods (NASDAQ:SMPL) is a mid-cap growth stock worth biting into. Goldman Sachs agrees. What's more, not only is SMPL stock sporting solid double-digit sales gains which have that firm's attention, there's a delicious-looking price chart for strong risk-adjusted positioning.Technically, this mid-cap growth stock is on the cusp of establishing a double-bottom or "W" base on the weekly time frame. Even in healthy markets, all stocks correct. And with SMPL stock finding support off the 38% retracement level and an oversold stochastics well-positioned to back up a durable bottom, SMPL stock has all the right ingredients for an imminent buy decision.Simply Good Foods Strategy: Purchase Simply Good Foods if the weekly pivot low is confirmed by price action above $25.13 and supported by a bullish crossover from stochastics.Investment accounts under Christopher Tyler's management do not currently own positions in securities mentioned in this article. The information offered is based upon Christopher Tyler's observations and strictly intended for educational purposes only; the use of which is the responsibility of the individual. For additional market insights and related musings, follow Chris on Twitter @Options_CAT and StockTwits More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 U.S. Stocks to Buy on Coronavirus Weakness * 7 Smart Blue-Chip Stocks to Buy Now * 7 Low-Volatility Stocks to Buy In Jittery Times The post 3 Mid-Cap Growth Stocks to Buy appeared first on InvestorPlace.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 10) AbbVie Inc (NYSE: ABBV ) Allergan plc (NYSE: AGN ) ...
Exelixis, Inc. (NASDAQ:EXEL) today announced encouraging results from the metastatic castration-resistant prostate cancer (CRPC) cohort of COSMIC-021, the phase 1b trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with locally advanced or metastatic solid tumors. The data will be presented on Thursday, February 13th during Poster Session A: Prostate Cancer at 11:30 a.m. – 1:00 p.m. PT and 5:30 – 6:30 p.m. PT at the 2020 American Society of Clinical Oncology’s Genitourinary Cancers Symposium (ASCO GU 2020), which is being held in San Francisco, California, February 13 – 15, 2020.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 28) 10X Genomics Inc (NASDAQ: TXG ) Acceleron Pharma Inc ...
Exelixis, Inc. (NASDAQ: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of CABOMETYX® (cabozantinib) in Japan, has applied to the Japanese Ministry of Health, Labor and Welfare (MHLW) for Manufacturing and Marketing Approval of cabozantinib as a treatment for patients with unresectable hepatocellular carcinoma (HCC) that had progressed after prior systemic therapy.
With rents soaring in other Bay Area biotech hubs, Alameda is staking its claim as an industry hotspot. Three companies — cancer drug developer Exelixis Inc., medical device company Penumbra Inc. and the diabetes care unit of Abbott Laboratories — are expanding in the East Bay island city. "It's Alameda's time again," said Joe Ernst, principal and founder of srmErnst Development Partners.
Roche (RHHBY) submits sBLA for the label expansion of the Tecentriq-Avastin combo to treat HCC patients who have not received prior systemic therapy.
Exelixis, Inc. (NASDAQ: EXEL) today announced phase 1/2 clinical trial results from the combination of cabozantinib (CABOMETYX®) and nivolumab (Opdivo®) with or without ipilimumab (Yervoy®) in advanced hepatocellular carcinoma (HCC). Data from the cabozantinib combination cohort of the CheckMate 040 trial will be presented on Friday, January 24 during Rapid Abstract Session B from 7:00 – 7:45 a.m. PT at the 2020 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI), which is being held in San Francisco, California, January 23-25, 2020. The data will also be included in Poster Session B from 12:00 – 1:30 p.m. PT and 4:30 – 5:30 p.m. PT on January 24.
The company had about $500M in debt 10 years ago and was down to 80 employees five years ago. Today it's debt-free, hiring and taking more space in Alameda.
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Exelixis, Inc. (Nasdaq: EXEL) today announced its key priorities and anticipated milestones for 2020-21, including generating top-line data from key clinical trials, completing enrollment of ongoing studies, initiating new pivotal trials, and progressing its mid-stage and early pipeline. The company intends to make appropriate investments to maximize the clinical development opportunities for CABOMETYX® (cabozantinib), which Exelixis believes could lead to as many as four additional approved indications by year-end 2021, while concurrently working to advance a pipeline of potential new Exelixis medicines through internal drug discovery and business development.